Last reviewed · How we verify
NCT07245966
Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis
trial in Sepsis in 20 participants. Completed in 28 February 2025.
31 January 2025
Quick facts
| Lead sponsor | Prince of Songkla University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 June 2024 |
| Primary completion | 31 January 2025 |
| Estimated completion | 28 February 2025 |
| Sites | 1 location across Thailand |
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
Prince of Songkla University
Who can join
18 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
As the general treatment method for infectious diseases is to prescribe antibiotics which can be complete at the empirical treatment with the control of the sources of infection, the types of antibiotics that contain the broad spectrum and the proper dose to reduce the severity of infection play an important role. Especially, patients with sepsis should receive antibiotics within 1 hours after the diagnosis since the delay of 1 hour will decrease the rate of survival by 7.6 percent. Ceftriaxone is considered to be Cephalosporin, the antibiotics in the group of β-lactams antibiotic which kills bacteria by preventing the creation of significant cell walls. Ceftriaxone is soluble and can be excreted by the kidney. It is a β-lactams broad spectrum which can kill bacteria broadly including various types of gram-positive and gram-negative. The effectiveness of Ceftriaxone is in accord with the percentage of time that the level of the drug is beyond the minimum inhibitory concentration. According to the research in animals conducted by Craig WA and others, the drug effect to prevent the bacteria growth will occur when the %ft\>MIC is more than at least 40%. The rate of prevention will reach the maximal bactericidal effect when the %ft\>MIC is equal to 60 to 70%. At the moment, physicians prefer the 60 to 70% of %ft\>MIC in the group of Cephalosporins drugs as the main pharmacodynamics to cope with infections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07245966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Prince of Songkla University trials
Trials by the same sponsor.
- NCT06841133 — Chinese Art Activities or Combined With Peer Group Participation on Psychological Well Being · NA · not yet recruiting
- NCT06837116 — Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers · EARLY_PHASE1 · completed
- NCT06476652 — Effect of Simple Simulator-based Training on Initial Performance of Novices Iultrasound-guided Adductor Canal Block · enrolling by invitation
- NCT06265870 — Specific Versus Empirical Anthelminthic Treatment in Eosinophilia · NA · recruiting
- NCT06219525 — Higher and Standard Doses of Enteral Zinc Supplementation in Very Preterm Infants · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07245966 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prince of Songkla University
- Last refreshed: 24 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07245966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing